COPD

This approval by the FDA follows positive findings from the pivotal BOREAS and NOTUS trials on adults with uncontrolled COPD.

A phase 3 trial found mirtazapine ineffective in reducing breathlessness in respiratory disease patients, urging caution with off-label antidepressant use.

This model and its service components may be implemented in the future to allow for improvements to primary care programs, with the goal being benefits to patients with COPD.

In this summary of major news in pulmonology covered in June 2024, approvals by the FDA, new episodes of Lungcast, news on COPD, and more are highlighted.

Ensifentrine, a PDE3 and 4 inhibitor from Verona Pharma, was associated with significantly improved lung function and reduced COPD exacerbations over 24 weeks.

The panel discusses emerging treatment approaches in COPD and reviews the study design and topline results from the BOREAS trial investigating dupilumab.

These data indicate the benefits of implementing individual protective measures in winter by patients with COPD.

Igor Barjaktarevic, MD, PhD, discusses the evolving treatment landscape in COPD, highlighting current treatment approaches and novel therapies on the horizon.

Experts on respiratory diseases discuss the GOLD treatment guidelines for COPD and discuss research that is informing treatment strategies.

Focusing on the role of eosinophils in diagnosing COPD, the panel discusses how often they should be tested, the cut-off value, and the natural changes of eosinophils in the disease course.

The panel discusses unmet needs in the COPD treatment landscape, highlights the shortcomings of current treatment strategies, and provides insights on diagnostic practices.

The FDA moved the target date for their decision on the dupilumab application by 3 months, citing a need for more efficacy data from its pivotal phase 3 trials.

Patients with AATD-associated lung disease on augmentation therapy participating in a health management program experienced negligible changes in self-perceived health status.

Igor Barjaktarevic, MD, PhD, provides insights on the evolving role of biomarkers in COPD, highlighting the role of eosinophils on informing treatment decisions.

1) Nicola A. Hanania, MD, MS, discusses what we have learned from asthma research on the involvement of type 2 inflammation that is applicable to COPD.

Use of dupilumab reduced exacerbations and improved lung function in COPD patients with type 2 inflammation.

The expert panel offers insights on the concept of extending phenotypes into treatable traits in patients with COPD.

Three experts on respiratory diseases give an overview of chronic obstructive pulmonary disease (COPD) and its impact on patients and the healthcare system.

This analysis indicates that quantitative interstitial abnormalities may indicate alterations in lung tissue processes that can result in short- and long-term consequences as far as symptoms.

These data highlight the benefits and drawbacks of the STAR and GOLD severity classification systems for COPD patients.

These data add to the growing body of literature on the impacts of different types of air pollution on respiratory conditions such as COPD and asthma.

In this Month in Review article for March, news on topics such as asthma and the impacts of pollution in the pulmonology field were highlighted.

These data may have impactful clinical and health policy implications, given that hospitalizations for CAP are known to be common and given the frequency of incorrect diagnoses.

New data show COPD and IPF, among other interstitial lung diseases, are more significantly associated with poor 30-day outcomes from COVID-19 than asthma.

A new study suggests patients with either rheumatoid arthritis or osteoarthritis may be at a higher genetic susceptibility to develop COPD.

On March 07, 2024, Boehringer Ingelheim announced it would be instituting a $35 per month out-of-pocket cost cap for its portfolio of inhaler products, with this cap going into effect on June 01, 2024.

These mental health outcomes were seen among those with self-reported COPD and asthma, though not among individuals with objective diagnoses based on spirometry.

In this Q&A discussion, Bhatt discusses the recent news of dupilumab’s supplemental Biologics License Application for COPD patients with type 2 inflammation, as well as its significance.

The FDA’s decision is planned for June 2024, and follows the successful results of the BOREAS and NOTUS trials.

These data, given sustainability targets in healthcare, may be considered by clinicians and by patients discussing DPIs.